282 related articles for article (PubMed ID: 20615167)
21. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline.
Allen-Ramey FC; Duong PT; Riedel AA; Markson LE; Weiss KB
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):373-80. PubMed ID: 15521374
[TBL] [Abstract][Full Text] [Related]
22. Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma.
Makhinova T; Barner JC; Richards KM; Rascati KL
J Manag Care Spec Pharm; 2015 Dec; 21(12):1124-32. PubMed ID: 26679962
[TBL] [Abstract][Full Text] [Related]
23. Asthma-related health care resource use among patients starting fluticasone or montelukast therapy.
Allen-Ramey FC; Anstatt DT; Sajjan SG; Markson LE
Pharmacotherapy; 2005 Dec; 25(12):1752-60. PubMed ID: 16305295
[TBL] [Abstract][Full Text] [Related]
24. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources.
Anis AH; Lynd LD; Wang XH; King G; Spinelli JJ; Fitzgerald M; Bai T; Paré P
CMAJ; 2001 Mar; 164(5):625-31. PubMed ID: 11258208
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of spacer device use by patients with asthma and COPD.
Guss D; Barash IA; Castillo EM
J Emerg Med; 2008 Nov; 35(4):357-61. PubMed ID: 18757157
[TBL] [Abstract][Full Text] [Related]
26. Real-time asthma outreach reduces excessive short-acting β2-agonist use: a randomized study.
Zeiger RS; Schatz M; Li Q; Solari PG; Zazzali JL; Chen W
J Allergy Clin Immunol Pract; 2014; 2(4):445-456, 456.e1-5. PubMed ID: 25017534
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of patients treated with fluticasone propionate or montelukast sodium.
Allen-Ramey FC; Duong PT; Goodman DC; Sajjan SG; Nelsen LM; Markson L
Manag Care Interface; 2003 Aug; 16(8):30-5. PubMed ID: 12964550
[TBL] [Abstract][Full Text] [Related]
28. Beta2-agonists use during pregnancy and the risk of congenital malformations.
Eltonsy S; Forget A; Blais L
Birth Defects Res A Clin Mol Teratol; 2011 Nov; 91(11):937-47. PubMed ID: 21948561
[TBL] [Abstract][Full Text] [Related]
29. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.
Stern L; Berman J; Lumry W; Katz L; Wang L; Rosenblatt L; Doyle JJ
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):402-8. PubMed ID: 17042149
[TBL] [Abstract][Full Text] [Related]
30. Relationship between short-acting β2-adrenergic agonist use and healthcare costs.
Silver HS; Blanchette CM; Kamble S; Petersen H; Letter MA; Meddis D; Gutierrez B
Am J Manag Care; 2011 Jan; 17(1):19-27. PubMed ID: 21348565
[TBL] [Abstract][Full Text] [Related]
31. Inhaled corticosteroid use and outcomes in pregnancy.
Schatz M; Leibman C
Ann Allergy Asthma Immunol; 2005 Sep; 95(3):234-8. PubMed ID: 16200813
[TBL] [Abstract][Full Text] [Related]
32. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens.
O'Connor RD; Rosenzweig JR; Stanford RH; Gilmore AS; Ryskina KL; Legorreta AP; Stempel DA
Ann Allergy Asthma Immunol; 2005 Dec; 95(6):535-40. PubMed ID: 16400892
[TBL] [Abstract][Full Text] [Related]
33. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Korn S; Vogelmeier C; Buhl R
Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
[TBL] [Abstract][Full Text] [Related]
34. Asthma controller delay and recurrence risk after an emergency department visit or hospitalization.
Stanford RH; Buikema AR; Riedel AA; Camargo CA; Rey GG; Chapman KR
Respir Med; 2012 Dec; 106(12):1631-8. PubMed ID: 22990041
[TBL] [Abstract][Full Text] [Related]
35. Recent asthma exacerbations: a key predictor of future exacerbations.
Miller MK; Lee JH; Miller DP; Wenzel SE;
Respir Med; 2007 Mar; 101(3):481-9. PubMed ID: 16914299
[TBL] [Abstract][Full Text] [Related]
36. Predicting need for hospitalization in acute pediatric asthma.
Gorelick M; Scribano PV; Stevens MW; Schultz T; Shults J
Pediatr Emerg Care; 2008 Nov; 24(11):735-44. PubMed ID: 18955910
[TBL] [Abstract][Full Text] [Related]
37. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ; Gross GN; Brewster C; Spalitto A
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[TBL] [Abstract][Full Text] [Related]
38. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy.
Bollu V; Ejzykowicz F; Rajagopalan K; Karafilidis J; Hay JW
J Med Econ; 2013 Aug; 16(8):1082-8. PubMed ID: 23777224
[TBL] [Abstract][Full Text] [Related]
39. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination.
Angus R; Reagon R; Cheesbrough A
Int J Clin Pract; 2005 Feb; 59(2):156-62. PubMed ID: 15854190
[TBL] [Abstract][Full Text] [Related]
40. Beta-2 adrenergic agonists: focus on safety and benefits versus risks.
Ortega VE; Peters SP
Curr Opin Pharmacol; 2010 Jun; 10(3):246-53. PubMed ID: 20452285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
